Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

11.06.2024 - Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, ...

Related Keywords

Japan ,United States ,America , ,International Number Toll ,Exchange Commission ,B Development ,Women Health Indications ,Company Phase ,Mental Health America Platinum Bell Seal ,Fuji Pharma Co Ltd ,Acute Treatment ,Social Anxiety Disorder ,Subjective Units ,Distress Scale ,Major Depressive Disorder ,Key Pherine Mechanism ,Positive Exploratory Phase ,Data Study ,Vasomotor Symptoms ,Hot Flashes ,Premenstrual Dysphoric Disorder ,Mental Health America ,Platinum Bell Seal ,Cindy Anderson ,Chief Financial ,Exclusive Negotiation Agreement ,Fuji Pharma ,Fiscal Year ,Dial In Number ,South San Francisco ,Annual Report ,Ended March ,